HLA-G and cancer: Complementary approaches could also focus on γδ T cells, especially in MMRd cancers with MHCI defects 47, DCs 29,48, PD-1 and PI3K-γ expressing myeloid cells 49,50, the HLA-E and HLA-G molecules 20,35,51–56, WRN inhibitors 57 or TREM1 myeloid cells 58.